Provided by Tiger Trade Technology Pte. Ltd.

MasterBrand, Inc.

12.06
-1.7600-12.74%
Post-market: 12.02-0.0413-0.34%16:12 EST
Volume:7.98M
Turnover:95.51M
Market Cap:1.53B
PE:19.15
High:12.33
Open:10.99
Low:10.99
Close:13.82
52wk High:17.09
52wk Low:9.33
Shares:126.78M
Float Shares:106.28M
Volume Ratio:3.29
T/O Rate:7.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6298
EPS(LYR):0.9600
ROE:6.19%
ROA:4.73%
PB:1.11
PE(LYR):12.56

Loading ...

Stock Track | MasterBrand Plunges 16.71% After-Hours on Q4 Earnings Miss and Weak Outlook

Stock Track
·
Yesterday

MasterBrand Q4 net sales fall, plans $30 mln cost savings

Reuters
·
Yesterday

MasterBrand Q4 Adj. EPS $(0.02) Misses $0.14 Estimate, Sales $644.600M Beat $607.600M Estimate

Benzinga
·
Yesterday

BRIEF-MasterBrand Q4 Adjusted EPS USD -0.02

Reuters
·
Yesterday

MasterBrand Inc: for Full Year 2026, Co Expects Addressable Market to Be Down Mid-Single Digits

THOMSON REUTERS
·
Yesterday

MasterBrand Outlook Q1 Adjusted EPS in Range of $-0.06 to $0.00

THOMSON REUTERS
·
Yesterday

MasterBrand Inc: $30 Mln of Cost Rationalization Expected to Be Achieved in 2026

THOMSON REUTERS
·
Yesterday

MasterBrand Inc Outlook Q1 Net Sales YoY Decrease of Mid-Single-Digit to High-Single-Digit Percentage

THOMSON REUTERS
·
Yesterday

Earnings Preview: MasterBrand, Inc.: This quarter’s revenue is expected to decrease by 16.14%, and institutional views are cautious

Earnings Agent
·
Feb 03

MasterBrand Inc. Partners with Cambria to Debut Feature Kitchen at KBIS 2026

Reuters
·
Jan 29

MasterBrand Inc. to Announce Financial Results and Host Conference Call

Reuters
·
Jan 14

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

GlobeNewswire
·
Dec 18, 2025

BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

GlobeNewswire
·
Dec 09, 2025

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

GlobeNewswire
·
Dec 02, 2025

Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America

prnewswire
·
Nov 26, 2025

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire
·
Nov 24, 2025

We Analyzed 5,000 Calls to Find Out What CEOs Really Think About Tariffs -- WSJ

Dow Jones
·
Nov 23, 2025

MasterBrand on Track for Lowest Close Since May 2023 -- Data Talk

Dow Jones
·
Nov 19, 2025

MasterBrand Inc - FTC Issues Second Request for MasterBrand-American Woodmark Merger - SEC Filing

THOMSON REUTERS
·
Nov 08, 2025

MasterBrand and American Woodmark Receive FTC Second Request for Merger Review

Reuters
·
Nov 08, 2025